Xeris Biopharma Holdings SEC Filings

Xeris Biopharma (XERS) reported an insider transaction by an officer. On 11/11/2025, the reporting person sold 16,667 shares of common stock at a weighted average price of $7.3976, executed under a Rule 10b5-1 trading plan.

Following the sale, the filer directly beneficially owned 1,336,843 shares. The sale price reflects multiple trades between $7.290 and $7.750. The reporting person is the company’s Chief Legal Officer and Corporate Secretary.

Xeris Biopharma reported stronger Q3 results. Total revenue reached $74.380 million (up 37.1% year over year), led by Recorlev $36.975 million, Gvoke $25.151 million, and Keveyis $11.937 million. Operating income was $6.731 million versus a loss a year ago, and net income was $621 thousand.

For the first nine months, revenue was $206.038 million with a net loss of $10.527 million. Cost discipline and mix improved gross costs: cost of goods sold fell to 14.8% of product revenue in Q3 from 25.7% a year earlier, aided by fewer inventory write-offs.

Cash and cash equivalents were $91.598 million and total cash, cash equivalents and restricted cash were $95.619 million. Net debt stood at $219.469 million (including $33.6 million of 2028 convertible notes and $188.045 million of 2029 loans). Stockholders’ equity (deficit) improved to $(0.861) million from $(29.615) million at year-end. Management believes cash resources are sufficient for at least the next 12 months, while noting ongoing net losses and market risks.

Xeris Biopharma Holdings, Inc. furnished an 8-K announcing a press release with results of operations and business highlights for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1.

The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference except as specifically set forth.

Xeris Biopharma Holdings insider Kevin McCulloch, listed as President and Chief Operating Officer, reported a transaction dated 10/02/2025. The filing shows 733 shares of common stock were disposed of at $8.31; the explanation states these shares were withheld by the issuer to satisfy tax and withholding obligations in connection with the net settlement of restricted stock units that vested on that date. After the reported transaction, Mr. McCulloch beneficially owns 1,700,426 shares directly. The report also lists 25,000 shares held indirectly by his spouse, with the reporting person disclaiming beneficial ownership except for pecuniary interest.

Xeris Biopharma Holdings, Inc. (XERS) Form 4 discloses insider reporting by Kevin McCulloch, President and Chief Operating Officer. On September 11, 2025 Mr. McCulloch, acting as trustee of the Charles R. McCulloch Trust, caused the trust to distribute 2,000 shares of Xeris common stock to a trust beneficiary; the Form notes no sale occurred in the transfer. The filing reports Mr. McCulloch's beneficial ownership following the transaction as 1,701,159 shares and an indirect holding of 25,000 shares attributable to his spouse. The reporting person disclaims beneficial ownership of distributed shares except to the extent of pecuniary interest.

Xeris Biopharma (XERS) reports a proposed sale under Rule 144 consisting of 15,500 common shares tied to restricted stock units granted by the issuer. The filing shows these shares were acquired on 06/04/2025 as Restricted Stock Units and have an aggregate market value of $121,055. The sale is scheduled approximately for 09/11/2025 through Morgan Stanley Smith Barney LLC on the NASDAQ market. The company reports 161,480,367 shares outstanding, and the filer certifies they are not aware of undisclosed material adverse information.

Jeffrey W. Sherman, a director of Xeris Biopharma Holdings, Inc. (XERS), reported insider transactions on 08/28/2025. He exercised a stock option to acquire 47,040 shares at an exercise price of $6.66 and, on the same date, sold 42,232 shares at a weighted-average price of $7.9209. After these transactions he beneficially owned 219,188 shares directly and an additional 5,400 shares indirectly through the Jeffrey W Sherman Living Trust, for a disclosed total of 224,588 shares reported on this Form 4. The option exercised was originally granted in 2016 (assumed in an acquisition) and vests fully; the option grant underlying the exercised shares shows an expiration date of 10/01/2026.

Xeris Biopharma Holdings, Inc. (XERS) filed a Form 144 reporting a proposed sale of 42,232 common shares with an aggregate market value of $334,511.23. The filing shows the shares represent part of total outstanding common shares of 161,480,367 and names Morgan Stanley Smith Barney LLC as the broker on NASDAQ with an approximate sale date of 08/28/2025.

The securities were acquired and are being sold on 08/28/2025 via a stock option exercise from the issuer, with payment made in cash. The filer indicates there were no securities sold in the past three months to report and affirms no undisclosed material adverse information.

Insider sale of XERS common stock reduced holdings: Director John Johnson sold 107,500 shares of Xeris Biopharma common stock on 08/13/2025 at a weighted average price of $7.3159 per share, leaving him with 833,483 shares beneficially owned. The Form 4 lists the sale as a direct disposition and notes the reported price is a weighted average reflecting multiple trades priced between $7.250 and $7.420. No derivative transactions or additional changes in indirect ownership are reported. The filing was signed by an attorney-in-fact on behalf of the reporting person.